Synapse - Dean Bajorin

Search Within

Dean Bajorin

Results (663)

Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials

Meeting Abstract

Sonpavde, G.; Pond, G. R.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.; Regazzi, A. M.; Mullane, S. A.; Necchi, A.; Raggi, D.; Lee, J. L.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Histologic determinants of long-term overall survival in patients (pts) with germ cell tumors (GCT)

Meeting Abstract

Funt, S.; Patil, S.; Feldman, D. R.; Motzer, R. J.; Bajorin, D. F.; Sheinfeld, J.; Tickoo, S.; Reuter, V. E.; Bosl, G. J.
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045

Meeting Abstract

De Wit, R.; Bajorin, D. F.; Bellmunt, J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Comparison of somatic mutation profiles from cell free DNA (cfDNA) versus tissue in metastatic urothelial carcinoma (mUC)

Meeting Abstract

Cheng, M. L.; Shady, M.; Cipolla, C. K.; Funt, S.; Arcila, M. E.; Al-Ahmadie, H.; Rosenberg, J. E.; Bajorin, D. F.; Berger, M. F.; Tsui, D.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Genomic comparison of matched primary and metastatic germ cell tumors (GCT)

Meeting Abstract

Audenet, F.; Donoghue, M.; Pietzak, E. J.; Isharwal, S.; Cheng, M. L.; Iyer, G.; Funt, S.; Bajorin, D. F.; Al-Ahmadie, H.; Reuter, V. E.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Single arm phase I/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus Calmette Guerin (NCT01259063)

Journal Article

Dalbagni, G.; Benfante, N.; Sjoberg, D. D.; Bochner, B. H.; Donat, S. M.; Herr, H. W.; McCoy, A. S.; Fahrner, A. J.; Retinger, C.; Rosenberg, J. E.; more...
Bladder Cancer (2017)

Fulltext@MSK | Save

Keynote-045: Open-label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer

Meeting Abstract

Quinn, D.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
Asia-Pacific Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) of pembrolizumab vs chemotherapy for previously treated advanced urothelial cancer (UC) in KEYNOTE-045

Meeting Abstract

Quinn, D.; Vaughn, D. J.; Bellmunt, J.; de Wit, R.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
Asia-Pacific Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

Meeting Abstract

Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; more...
European Journal of Cancer (2017)

Fulltext@MSK | Save

Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets

Journal Article

Pietzak, E. J.; Bagrodia, A.; Cha, E. K.; Drill, E. N.; Iyer, G.; Isharwal, S.; Ostrovnaya, I.; Baez, P.; Li, Q.; Berger, M. F.; more...
European Urology (2017)

Fulltext@MSK | Save